- Home
- SCYX vs INKT Comparison
SCYX vs INKT Comparison
Compare SCYX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- INKT
- Stock Information
- Founded
- SCYX 1999
- INKT 2017
- Country
- SCYX United States
- INKT United States
- Employees
- SCYX N/A
- INKT N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SCYX Health Care
- INKT Health Care
- Exchange
- SCYX Nasdaq
- INKT Nasdaq
- Market Cap
- SCYX 28.5M
- INKT 28.8M
- IPO Year
- SCYX 2014
- INKT 2021
- Fundamental
- Price
- SCYX $0.75
- INKT $39.62
- Analyst Decision
- SCYX
- INKT Strong Buy
- Analyst Count
- SCYX 0
- INKT 2
- Target Price
- SCYX N/A
- INKT $37.50
- AVG Volume (30 Days)
- SCYX 145.5K
- INKT 2.4M
- Earning Date
- SCYX 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- SCYX N/A
- INKT N/A
- EPS Growth
- SCYX N/A
- INKT N/A
- EPS
- SCYX N/A
- INKT N/A
- Revenue
- SCYX $2,630,000.00
- INKT N/A
- Revenue This Year
- SCYX $463.61
- INKT N/A
- Revenue Next Year
- SCYX $310.80
- INKT N/A
- P/E Ratio
- SCYX N/A
- INKT N/A
- Revenue Growth
- SCYX N/A
- INKT N/A
- 52 Week Low
- SCYX $0.66
- INKT $4.56
- 52 Week High
- SCYX $2.29
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SCYX 38.69
- INKT 69.01
- Support Level
- SCYX $0.67
- INKT $6.80
- Resistance Level
- SCYX $0.75
- INKT $76.00
- Average True Range (ATR)
- SCYX 0.04
- INKT 4.65
- MACD
- SCYX 0.00
- INKT 4.24
- Stochastic Oscillator
- SCYX 33.06
- INKT 49.48
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.